All In Biotech

Drug Trial Radar · NCT05125302

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,059 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,059

Planned (sponsor's estimate)

Start

Jan 13, 2022

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis to determine dose selection for the main study. In the main study, after dose selection, children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo. Adolescents aged 12-17 years will be randomized to receive either low or high dose of Ubrogepant or placebo with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will receive oral tablets of the double-blind study intervention. There will be an option to take a second dose of double-blind study intervention (identical to initial dose), or rescue medication, at least 2 hours after the initial dose, for headache of moderate/severe intensity. Around 1059 participants will be enrolled in the study in approximately 120 sites in the United States. The study duration will be up to 6 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Migraine

Interventions

  • UbrogepantDrug

    Oral Tablet

  • Placebo-Matching UbrogepantDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 yearsTime frame: 2 hours after initial dose

Locations

129 sites in 2 countries. Site status is shown where the registry gives one.

  • Rehabilitation & Neurological Services /ID# 229969

    Huntsville, Alabama · Recruiting

  • The Center for Clinical Trials - Saraland /ID# 231546

    Saraland, Alabama · Recruiting

  • Velocity Clinical Research - Phoenix /ID# 274478

    Phoenix, Arizona · Recruiting

  • HealthStar Research Glenwood /ID# 275303

    Glenwood, Arkansas · Recruiting

  • HealthStar Research of Hot Springs /ID# 273256

    Hot Springs, Arkansas · Recruiting

  • Preferred Research Partners /ID# 230725

    Little Rock, Arkansas · Recruiting

  • Advanced Research Center /ID# 227962

    Anaheim, California · Recruiting

  • Neuro Pain Research Center /ID# 227966

    Fresno, California · Recruiting

  • Imax Clinical Trials /ID# 281436

    La Palma, California · Recruiting

  • Alliance for Research Alliance for Wellness /ID# 230546

    Long Beach, California · Recruiting

  • Children's Hospital Los Angeles /ID# 230596

    Los Angeles, California · Completed

  • Paradigm Clinical Research - Modesto, CA /ID# 280611

    Modesto, California · Recruiting

  • Excell Research, Inc /ID# 230899

    Oceanside, California · Recruiting

  • Paradigm Clinical Research - San Diego /ID# 269608

    San Diego, California · Recruiting

  • Lumos Clinical Research Center /ID# 231267

    San Jose, California · Recruiting

  • Pacific Clinical Research Management Group /ID# 231636

    Upland, California · Completed

  • Sunwise Clinical Research /ID# 230971

    Walnut Creek, California · Recruiting

  • Amicis Research Center /ID# 272621

    Winnetka, California · Recruiting

  • Paradigm Clinical Research - Aurora, CO /ID# 280612

    Aurora, Colorado · Recruiting

  • Children's Hospital Colorado - Aurora /ID# 231879

    Aurora, Colorado · Recruiting

  • IMMUNOe Research Centers /ID# 230879

    Centennial, Colorado · Completed

  • MCB Clinical Research Centers - Colorado Springs - South Parkside Drive /ID# 231625

    Colorado Springs, Colorado · Completed

  • New England Institute for Clinical Research /ID# 230635

    Stamford, Connecticut · Recruiting

  • Emerson Clinical Research Institute - Connecticut Avenue - Washington /ID# 231693

    Washington D.C., District of Columbia · Recruiting

  • Encore Medical Research of Boynton Beach LLC /ID# 246833

    Boynton Beach, Florida · Recruiting

  • Gulf Coast Clinical Research Center /ID# 230020

    Fort Myers, Florida · Recruiting

  • Sarkis Clinical Trials /ID# 227956

    Gainesville, Florida · Completed

  • Northwest Florida Clinical Research Group, LLC /ID# 231069

    Gulf Breeze, Florida · Completed

  • AGA Clinical Trials /ID# 230554

    Hialeah, Florida · Recruiting

  • Encore Medical Research /ID# 245682

    Hollywood, Florida · Recruiting

  • Advanced Research Institute of Miami /ID# 230292

    Homestead, Florida · Completed

  • Auzmer Research /ID# 239251

    Lakeland, Florida · Completed

  • Columbus Clinical Services, Llc /Id# 230880

    Miami, Florida · Recruiting

  • My Preferred Research LLC /ID# 227886

    Miami, Florida · Recruiting

  • Neurology & Pain Medicine /ID# 240168

    Miami, Florida · Completed

  • Medical Research Group of Central Florida /ID# 231632

    Orange City, Florida · Recruiting

  • Clinical Associates of Orlando, LLC /ID# 272619

    Orlando, Florida · Recruiting

  • Suncoast Clinical Research - Palm Harbor /ID# 229337

    Palm Harbor, Florida · Completed

  • FWD Clinical Research - Spring Hill /ID# 229815

    Spring Hill, Florida · Recruiting

  • University of South Florida- Neuroscience Institute /ID# 229324

    Tampa, Florida · Recruiting

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.